May 15, 2020 -- Codiak BioSciences released new preclinical data on its engEx platform at the American Society of Gene and Cell Therapy annual meeting.
Specifically, the company highlighted the use of its exoVACC vaccine platform to direct tropism for multiple cell lines in vitro and in vivo. The engEx platform loads exosomes with various therapeutic targets to alter tropism and target specific cells.
Codiak is developing the platform to target multiple pathways throughout the body to treat various types of cancer and enhance immune responses with an array of antigens. The modular platform is designed to incorporate multiple complex antigens, adjuvants, targeting ligands, and immune costimulatory molecules within a single exosome.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: